MADISON, Wis., June 15, 2016 /PRNewswire/ — Exact Sciences Corp. (Nasdaq: EXAS) today announced that the U.S. Preventive Services Task Force (USPSTF) issued its final 2016 colorectal cancer screening recommendations and clarified the inclusion of Cologuard® (FIT-DNA) on equal standing among the other included screening tests. “We believe the final recommendations provide an important level of clarity to patients, physicians and insurers and that Cologuard should receive the benefits given to A-rated preventive services under the Affordable Care Act,” said Kevin Conroy, Exact Sciences’ chairman and CEO.  “We thank the Task Force for carefully reviewing the body of scientific evidence supporting Cologuard and for providing this clear guidance.”

See more at: http://investor.exactsciences.com/investor-relations/press-releases/press-release-details/2016/Exact-Sciences-Cologuard-Included-in-Final-USPSTF-Colorectal-Cancer-Screening-Recommendations/default.aspx#sthash.DTINyP6b.dpuf